focus -WSS

focus

author：Wikipedia 2025-08-27 16:47:31 - browse：3273

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： In same hospitals, Black patients receive fewer opioids than white patients

focus

WSS

Astellas still sees hope in its gene therapy after four deaths

FDA's Woodcock to retire early next year

FDA panel issues narrow recommendation for Covid vaccine booster doses

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

In key trial, Verve's treatment lowers cholesterol levels in patients

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

knowledge

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Alkermes shareholders re

Hospitals look to new technology to keep health care workers safe

Affirmative action in medical school literally saved lives

American woman, child freed after being kidnapped in Haiti last month

Anesthesiologist group: stop taking Ozempic before surgery

Wegovy trial has doctors encouraged over new possibilities

Psychedelics group wrestles with new pharma identity

NYU radiologists take on the challenge of expensive MRI machines

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Anthos stroke drug appears safer than common blood thinner

Wikipedia

Surge of respiratory disease in China has likely explanation

Ransomware attacks on hospitals: Study outlines patient impact

What to know about Virgin Galactic's 1st mission taking paying customers to space

Anavex keeps shifting the goalposts in its clinical trials

Maui's cultural, historic landmarks damaged in the devastating wildfires

South Korea throws huge K

entertainment

focus

focus

focus